Early Hypothalamic Aromatase Loss Is Associated with Neuronal Insulin-Resistance Signaling During Progression of Experimental Alzheimer’s Disease
Open Access
Abstract
Alzheimer’s disease (AD) is increasingly recognized as a neurodegenerative disorder characterized by central insulin resistance and cerebral hypometabolism. The steroid hormone, 17β-estradiol (E2), interacts closely with insulin signaling pathways and is locally synthesized in the brain by the enzyme aromatase. However, the spatial and temporal dynamics of brain aromatase during AD progression and its relationship to central insulin resistance remain poorly understood. Using the 5xFAD mouse model, we examined whole-brain, regional, and neuron/astrocyte-specific alterations in aromatase expression along disease progression. Whole-brain aromatase expression remained unchanged at 2 months of age but progressively declined at 5 and 9 months, inversely correlating with amyloid-β plaque burden. Regional analysis of the cortex, hippocampal CA1, and hypothalamus revealed progressive aromatase loss in all regions; notably, the hypothalamus exhibited a significant decline at the earliest disease stage examined, preceding comparable changes in the cortex and hippocampus, while an age-related decline cannot be fully excluded, as only a single-aged wild-type (WT) control was used. Cell-level analysis revealed a progressive reduction in neuronal aromatase expression, whereas astrocytic aromatase displayed a biphasic response, increasing during early disease stages before declining at later stages. In parallel, neuronal insulin-resistance signaling increased progressively with disease advancement and was negatively correlated with neuronal aromatase expression across all regions examined (r = −0.82 to −0.87). Collectively, these findings demonstrate progressive regional and neuron/astrocyte-specific alterations in brain aromatase during the progression of amyloid pathology, identifying early hypothalamic vulnerability as a feature of AD-associated altered insulin signaling.Keywords
Funding Information
- National Institutes of Health (R01AG083947)
This publication has 67 references indexed in Scilit:
- Dysregulation of energy metabolism in Alzheimer's diseaseJournal of Neurology, 2024
- Cognitive Decline in Alzheimer’s Disease2024
- FABP7 drives an inflammatory response in human astrocytes and is upregulated in Alzheimer’s diseaseGeroScience, 2023
- Brain insulin resistance linked Alzheimer’s and Parkinson’s disease pathology: An undying implication of epigenetic and autophagy modulationInflammopharmacology, 2023
- Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective reviewMolecular and Cellular Biochemistry, 2022
- The connections of Locus Coeruleus with hypothalamus: potential involvement in Alzheimer’s diseaseJournal of Neural Transmission, 2021
- The Role of Skeletal Muscle Estrogen Receptors in Metabolic Homeostasis and Insulin Sensitivity2017
- Hormonal Influences on Cognition and Risk for Alzheimer’s DiseaseCurrent Neurology and Neuroscience Reports, 2010
- C677T Methylentetrahydrofulate Reductase and Angiotensin Converting Enzyme Gene Polymorphisms in Patients with Alzheimer’s Disease in Iranian PopulationNeurochemical Research, 2006
- Potential neuronal mechanisms of estrogen actions in synaptogenesis and synaptic plasticityCellular and Molecular Neurobiology, 1996